Condition: Carcinoma, Renal Cell · Sponsor: Jodi Maranchie
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
This description comes directly from the study's public registry record.
Morgan Pokora, RN · 412-623-4886 · pokoraml3@upmc.edu
Jodi Maranchie, MD · 412-605-3019 · maranchijk@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Department of Urology | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05127824